Home
Apnimed, Inc.

Apnimed, Inc. Market Share Analysis for June 2026

Learn about AD109 (aroxybutynin atomoxetine) and how it could address the neuromuscular cause of OSA. The potential power of AD109 is in a pill.

Health > Biotechnology and Pharmaceuticals

Domainapnimed.com

Year Founded2017

Employees51 - 200

Annual Revenue$5M - $10M

Apnimed, Inc.

Apnimed, Inc. (including company regionals)

apnimed.com

See more website traffic and engagement information

Apnimed, Inc. Revenue up to June 2026 is 5M - 10M

revenue generated by Apnimed, Inc. top domains

Apnimed, Inc. top domains revenue over 3 years

Revenue for Apnimed, Inc. top domains

apnimed.com5M - 10M

See more with Sales Intelligence

Total visits to Apnimed, Inc.'s top domains

Understand Apnimed, Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

apnimed.com45K

See more with Sales Intelligence

Avg. visit duration in Apnimed, Inc.'s top domains

Analyze Apnimed, Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

apnimed.com00:00:29

See more with Sales Intelligence

Avg. pageviews on Apnimed, Inc.'s top domains

See how Apnimed, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

apnimed.com2.05

See more with Sales Intelligence

Apnimed, Inc. top competitors by domain

Top similar sites in June 2026, ranked by their affinity

ensodata.comCompany NameEnsoDataEmployees51 - 200HQUnited States, Wisconsin, MadisonAnnual revenue$2M - $5MTotal visits6KHealth > Health - Other

Top technologies used by Apnimed, Inc.

These are the website technologies, by industry, used by Apnimed, Inc. top domains

Advertising (7)

Google Adsense

Widget (6)

Twemoji

Conversion & Analytics (2)

Google Analytics

Email Services (2)

Microsoft Exchange Online

More Technologies

9

See all

News & Signals from Apnimed, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsApnimed Inc. will develop AD109 on Jul 1st '27.Founded in 2017, Cambridge, Massachusetts-based Apnimed is focused on developing AD109, a once-daily pill combining the novel antimuscarinic drug aroxybutynin and selective norepinephrine reuptake inhibitor (sNRI) atomoxetine that was filed for FDA approval in April, with a fast-track designation, and is heading for a decision in the first quarter of 2027.

NewsApnimed Inc. was planning to go public on Jul 10th '26.July 10 (Reuters) - Apnimed, a late-stage clinical pharmaceutical company, filed for an initial public offering in the U.S. on Friday.

NewsApnimed Inc. hired Kevin Lind as Chief Executive Officer on Jun 2nd '26.* New Chief Financial Officer and Chief Legal Officer and Head of Corporate Affairs follow recent appointment of Kevin Lind as Chief Executive Officer, in a planned succession strategy preparing Apnimed for its next stage of growth